Clinical trials: Thoracic Cancer
Lung Cancer
A Retrospective Pharmacoeconomic Study of Lung Cancer
Lung cancer is the No. cause of cancer death in Taiwan. Yet most of lung cancer are diagnosed at late stage, not amenable to surgical resection.
- Trial name
- NCT01140958
- Volunteers
- 91 people
- Sponsor
- Taipei Medical University WanFang Hospital
Lung Adenocarcinoma
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
The purpose of this study is to confirm the safety of Apatinib at a dose level up to 750 mg/d with standard therapy of docetaxel (60 mg/m²) in advanced lung adenocarcinoma patients harboring wild-type EGFR after failure of first…
- Trial name
- NCT02691871
- Testing
- Apatinib (250 mg/d) + Docetaxel (60 mg/m2), Apatinib (500 mg/d) + Docetaxel (60 mg/m2), Apatinib (750 mg/d) + Docetaxel (60 mg/m2)
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer, Esophageal Cancer
Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery
Patients on this observation study must have planned treatment regimen with concurrent CRT followed by planned surgery, which is considered as standard of care for their disease.
- Trial name
- NCT03095209
- Testing
- Carboplatin, Paclitaxel, Radiation Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Fox Chase Cancer Center
Lung Cancer
A Study of Lung Cancer Risk
The researchers are doing this study to learn more about factors that may increase the risk of lung cancer in people who have never smoked.
- Trial name
- NCT07701733
- Testing
- Questionnaire
- Where
- 7 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Carcinoma
FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma
This is an open-label, randomized phase II trial of a monoclonal antibody (mAb) drug immunoconjugate, SGN-15, administered weekly in combination with weekly docetaxel.
- Trial name
- NCT00086333
- Testing
- SGN-15, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Seagen Inc.
Neoplasm Metastasis
Proteome-based Immunotherapy of Lung Cancer Brain Metastases
Trial Hypothesis: Acute, progressing lethal neurooncological process can be transferred into chronic and non-lethal, the survival rates and life quality can be improved by of control of tumor cells (TCs) quantity and targeted…
- Trial name
- NCT01782287
- Testing
- Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes, Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- NeuroVita Clinic
Metastatic NSCLC, Recurrent NSCLC
Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC
This is a single-arm, prospective, exploratory clinical study aiming to evaluate the efficacy and safety profile of sintilimab combined with anlotinib hydrochloride and platinum-containing dual-agent chemotherapy regimens in…
- Conditions
- Metastatic NSCLC, Recurrent NSCLC, Advanced Non-Small Cell Squamous Lung Cancer
- Trial name
- NCT04846452
- Testing
- Sintilimab + Anlotinib + Pemetrexed + Cisplatin or Carboplatin, Sintilimab + Anlotinib + Albumin Paclitaxel + Carboplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Lung Cancer, Non-small Cell
Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment
A prospective, single center, single arm, phase II clinical trial of Pyrotinib combined with pemetrexed plus carboplatin in the first-line treatment of patients with HER2 mutant or amplified recurrent / metastatic non-small cell…
- Trial name
- NCT04706949
- Testing
- Pyrotinib combined with pemetrexed plus carboplatin
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Fudan University
EGFR, Lung Cancer (NSCLC)
Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC
This study will evaluate the novel, oral EGFR TKI, zipalertinib, in the adjuvant ctDNA-adapted treatment of stage IA2 to IIIC atypical EGFR-mutant NSCLC after completion of definitive therapy with a primary endpoint of molecular…
- Conditions
- EGFR, Lung Cancer (NSCLC), Non Small Cell Lung Cancer
- Trial name
- NCT07802834
- Testing
- Zipalertinib
- Volunteers
- 42 people
- Sponsor
- Stanford University
Lung Cancer
Ambispective Registry of Patients Affected by Lung Cancer
Lung cancer is one of the most common cancers and the leading cause of cancer-related death. It is often diagnosed late, and there are different types of lung cancer.
- Trial name
- NCT07274163
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Esophageal Squamous Cell Carcinoma, Enteral Nutrition Therapy
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
This is a randomized, prospective, multicenter study.
- Conditions
- Esophageal Squamous Cell Carcinoma, Enteral Nutrition Therapy, Chemoradiotherapy
- Trial name
- NCT02399306
- Testing
- Enteral nutrition, radiotherapy
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Lung Tumor, Solitary Pulmonary Nodule
Feasibility of Multi-Energy Digital Radiography Detector for Lung Lesions Detection
A single-centre, industry sponsored, pilot study to assess the feasibility of Single Exposure Dual Energy Subtraction with a Multi-Energy digital radiography detector as an imaging platform for lung lesion detection.
- Trial name
- NCT03528733
- Testing
- Multi-Energy Digital Radiography Detector System
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- KA Imaging Inc.
Non-Small Cell Lung Cancer
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III NSCLC in separate cohorts of locally advanced and…
- Trial name
- NCT00787852
- Testing
- Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47, Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Brown University
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Advanced Cancer, Lung Cancer
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with…
- Conditions
- Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- TIG-006 (NCT05060432)
- Testing
- EOS-448, pembrolizumab, inupadenant
- Where
- 42 sites in United States, Belgium and 4 more
- Volunteers
- 153 people
- Sponsor
- iTeos Belgium SA
Non Small Cell Lung Cancer (NSCLC)
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with…
- Trial name
- WAYWIN103 (NCT07206498)
- Testing
- Osimertinib (Tagrisso®), WSD0922-FU
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Wayshine Biopharm, Inc.
Central Nervous System Neoplasms, Neoplasm Metastasis
Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy
The goal of this study is to find the maximum dose of a drug, temozolomide, that can safely be given to subjects with brain tumors. Past studies showed that the maximum dose of temozolomide was limited by low blood counts.
- Trial name
- CN-306 (NCT00629187)
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Tufts Medical Center
Metastatic Cancer Lung, Metastatic Ovarian Cancer
[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging
This is a clinical trial category C as this is a first in man trial with an unapproved investigational product. Nevertheless the risk is considered low due to the low dose ≤ 10μg.
- Trial name
- NCT03242993
- Testing
- [18F]-AzaFol, folarell
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- University of Lausanne Hospitals
Non-Small Cell Lung Cancer
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
This study is a single-center, prospective, single-arm exploratory clinical study of hypofractionated radiotherapy followed by tislelizumab and anlotinib neoadjuvant and adjuvant therapy.
- Trial name
- NCT06379087
- Testing
- Anlotinib Hydrochloride Capsule, Tislelizumab Injection, Hypofractionated Radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ji Yongling
Non Small Cell Lung Cancer, Neoadjuvant Therapy
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
A phase II, single-arm, open-label study evaluating feasibility, safety and efficacy of combined chemotherapy and pembrolizumab as neoadjuvant/adjuvant therapy in stage IIa-IIIB NSCLC adult patients followed by adjuvant PD-(L)1…
- Conditions
- Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor
- Trial name
- NeoP (NCT05383716)
- Testing
- Pembrolizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital